# Arcturus Therapeutics

Type: Company (ARCT)

Source: GetYourBrief — https://getyourbrief.com/entity/arcturus-therapeutics
Canonical HTML page: https://getyourbrief.com/entity/arcturus-therapeutics

## Timeline

- **2026-03-03**: Q4 Earnings Release — Both companies scheduled to report full-year 2025 financial results.
- **2025-09-15**: ARCT-032 Phase 1b — Arcturus releases positive interim data for Cystic Fibrosis candidate.
- **2023-11-28**: Kostaive Approval — Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.

## Recent coverage (6 stories, network-wide)

### Analyst Sentiment Shifts: Xponential Fitness Downgraded, Rocket Lab Initiated
2026-03-19 14:56:55 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A significant wave of analyst rating changes has hit the market, featuring a notable downgrade for boutique fitness giant Xponential Fitness and a bullish initiation for space leader Rocket Lab. These shifts underscore a broader institutional reassessment of growth trajectories across the fitness, aerospace, and biotechnology sectors.
Full story: https://getfinancebrief.com/story/analyst-sentiment-shifts-xponential-fitness-rocket-lab

### Analyst Sentiment Diverges for Biotech Leaders Apogee and Arcturus
2026-03-19 14:56:50 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Apogee Therapeutics and Arcturus Therapeutics experienced a wave of conflicting analyst activity on Thursday, with both companies facing significant downgrades alongside new initiations. This institutional tug-of-war highlights the increasing volatility and selective nature of investment in mid-cap biotechnology firms.
Full story: https://getbiobrief.com/story/apogee-arcturus-analyst-ratings-divergence

### Mixed Analyst Sentiment Hits Biotech: Apogee and Arcturus Under Scrutiny
2026-03-19 14:56:16 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Apogee Therapeutics and Arcturus Therapeutics faced simultaneous downgrades and initiations in a single trading session, highlighting a sharp divide in analyst sentiment. This volatility reflects broader market uncertainty regarding clinical-stage biotech valuations and the specific pipelines of these immunology and mRNA specialists.
Full story: https://gethealthbrief.com/story/biotech-analyst-activity-apogee-arcturus

### Biotech Execution in Focus: Arcturus and Rigel Set for Q4 Earnings Results
2026-03-02 22:55:18 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution. Investors are focused on Arcturus's mRNA vaccine rollout in Japan and Rigel's integration of its expanded oncology portfolio.
Full story: https://getfinancebrief.com/story/arcturus-rigel-q4-2025-earnings-preview

### Arcturus and Rigel Q4 Previews: mRNA Innovation vs. Oncology Commercialization
2026-03-02 22:54:15 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.
Full story: https://getbiobrief.com/story/arcturus-rigel-q4-2025-earnings-preview

### Biotech Earnings Preview: Arcturus and Rigel Set for Pivotal Q4 Reports
2026-03-02 22:53:40 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.
Full story: https://gethealthbrief.com/story/arcturus-rigel-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.